Cabaletta Bio Inc. (Nasdaq: CABA) entered into a 10‑year commercial supply agreement with Cellares, the first integrated development and manufacturing organization to provide automated Cell Shuttle and Cell Q platforms for the production of its investigational CAR‑T therapy, rese‑cel.
Under the agreement, Cellares will manufacture and supply rese‑cel using its automated platforms once the product receives FDA approval. The partnership enables Cabaletta to produce thousands of batches per year with minimal capital investment, potentially lowering the cost per batch to one of the lowest in the autologous cell‑therapy market.
The deal is a strategic enabler for Cabaletta’s clinical and commercial roadmap. The company plans to submit a Biologics License Application for rese‑cel in myositis in 2027 and will present translational data from Cellares‑manufactured product at the ASGCT conference in May 2026. The agreement also positions Cabaletta to support future pipeline candidates built on its CABA platform.
Cabaletta’s financial profile underscores the importance of the agreement. The company disclosed conditions raising substantial doubt about its ability to continue as a going‑concern beyond Q4 2026 without additional financing. It is seeking to double its authorized common shares from 300 million to 600 million, a move that could dilute existing shareholders. The manufacturing partnership therefore represents a critical cost‑saving lever that could help the company meet its capital needs and sustain operations.
CEO Steven Nichtberger said the agreement “provides the cost‑efficient foundation we need to expand access to rese‑cel while building a profitable business.” He added that the partnership marks a “fundamental shift toward automated manufacturing that is demonstrably ready.” Cellares CEO Fabian Gerlinghaus noted, “That is exactly what we built Cellares for.”
Analysts have reiterated buy ratings for Cabaletta, citing the company’s progress in clinical trials and the strategic advantage of automated manufacturing. The no‑preconditioning regimen and partnership with Cellares were highlighted as key differentiators that could accelerate commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.